Drug Dosing in Altered Renal Function

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/26

encourage image

There's no tags or description

Looks like no tags are added yet.

27 Terms

1
New cards

Acute Kidney Injury (AKI)

Rapid decline in filtration/clearance across all three buckets requiring acute renal dose adjustments until kidney function recovers:

2
New cards

Pre-Renal

Volume depletion (GI losses, hemorrhage), decreased effective circulatory volume (heart failure exacerbation, cirrhosis with ascites), or functional hemodynamic shifts (afferent/efferent arteriolar tone changes).

3
New cards

Intrinsic:

ATN (#1 most common; ischemia/sepsis or nephrotoxins), AIN (#2 most common; NSAIDs, beta-lactams), vascular (< 5%), and glomerular (< 5%).

4
New cards

Post-Renal:

Outflow obstruction (sharp drop in urine output + markedly elevated SCr; e.g., acyclovir, methotrexate, tumor lysis syndrome)

5
New cards

Chronic Kidney Disease (CKD

Multifactorial progressive decline in clearance due to loss of nephron mass, glomerular capillary hypertension/hypertrophy (once initial afferent prostaglandin vasodilation and efferent Ang II vasoconstriction compensation fails), and albuminuria (enlarged glomerular pores altering clearance).

6
New cards

Absorption / Bioavailability (A):

Essentially unchanged by CKD itself (though CKD Stages 3–5 exhibit decreased gastric motility and decreased gastric acidity from chronic inflammation, which can alter GI/hepatic non-renal metabolism and drug transport).

7
New cards

4 Downstream PK Consequences of Increased

  • Decreased peak concentrations (lower serum concentration immediately post-dose)

  • Increased half-life (t1/2) (less drug in serum available for renal/hepatic elimination)

  • Delayed time to steady state

    • Increased risk of elevated trough concentrations if dosed at standard intervals


8
New cards

Two Primary Adjustment Strategies:

  • Decrease the dose

    • Increase (extend) the dosing interval


9
New cards

When to Adjust:

Generally required when a drug (or an active metabolite, such as morphine or codeine) is >= 30% cleared by the kidney.

10
New cards

Big Tough Alligators Prefer Dainty Dishes")

B — Beta-Lactams & Antimicrobials:B — Beta-Lactams & Antimicrobials:

T — Therapeutic Drug Monitoring (TDM):

A — Anticoagulants & Antiarrhythmics:

P — Pain Management

D — Diabetes Agents:

D — Digoxin:

11
New cards

B — Beta-Lactams & Antimicrobials:B — Beta-Lactams & Antimicrobials:

  • Most antibiotics require renal dose adjustments (e.g., ampicillin-sulbactam, cefepime, meropenem, levofloxacin, TMP-SMX).

  • Antibiotic Exceptions — NO Renal Dose Adjustment Needed (MEMORIZE):

    • Ceftriaxone (only cephalosporin/beta-lactam underlined exception)

    • Azithromycin

    • Doxycycline

    • Moxifloxacin

    • Linezolid

    • Rifampin (plus nafcillin on slide)


12
New cards

T — Therapeutic Drug Monitoring (TDM):

  • Vancomycin, Gentamicin (aminoglycosides).



13
New cards

A — Anticoagulants & Antiarrhythmics:

  • Anticoagulants: LMWH (enoxaparin) and DOACs (apixaban, rivaroxaban, dabigatran, edoxaban).

    • Antiarrhythmics: Dofetilide, Sotalol (note: amiodarone does NOT require renal adjustment).


14
New cards

P — Pain Management

Morphine (avoid in CrCl < 30 / HD due to accumulation of renally cleared active metabolites causing respiratory depression/neurotoxicity), gabapentin (plus meperidine, pregabalin).

15
New cards

D — Diabetes Agents:

Metformin (reduce max dose to 500 mg BID at eGFR 30–44; discontinue at eGFR < 30) and sulfonylureas (hypoglycemia risk).

16
New cards

Allopurinol Pearl

Only requires renal dose adjustment when initiating therapy; once established on a maintenance dose, do not reduce it solely for declining CrCl.

17
New cards

Rosuvastatin Pearll

Hydrophilic statin (> 30% renal clearance) requiring dose reduction to max 10 mg daily when CrCl < 30 mL/min (atorvastatin requires no renal adjustment)

18
New cards

Enoxaparin (Lovenox) 1 mg/kg SQ BID

CrCl < 30 mL/min: 1 mg/kg SQ once daily (q24h)

19
New cards

Apixaban (Eliquis) 5 mg PO BID

Meets >= 2 of 3 criteria (Age >= 80 yrs, Weight <= 60 kg, SCr >= 1.5 mg/dL): 2.5 mg PO BID

20
New cards

Rivaroxaban (Xarelto)

20 mg PO daily CrCl 15–50 mL/min: 15 mg PO daily (Note: Avoid if CrCl < 30 for DVT/PE)

21
New cards

Dabigatran (Pradaxa) 150 mg PO BID

CrCl 15–30 mL/min: 75 mg PO BID

22
New cards

Edoxaban (Savaysa) 60 mg PO daily

CrCl 15–50 mL/min OR Weight <= 60 kg: 30 mg PO daily

23
New cards

General Rule:

Always calculate Cockcroft-Gault CrCl and consult Lexicomp/Micromedex/package inserts; check serum drug levels for narrow therapeutic index medications (e.g., vancomycin, gentamicin) and administer supplemental doses post-HD when indicated.

24
New cards

Hemodialysis (HD)

Clearance depends on drug properties, dialyzer membrane/filter, and session parameters.

25
New cards

Peritoneal Dialysis (PD)

Targets urea clearance of ~10 mL/min with minimal effect on drug clearance -> if specific PD guidance is unavailable, use dosing recommendations for an estimated CrCl of 10–15 mL/min.

26
New cards

Continuous Renal Replacement Therapy (CRRT)

Limited but growing evidence -> general rule of thumb is to assume an estimated CrCl of ~30 mL/min (clears drugs with larger Vd and predominantly renal clearance more extensively over 24 hours than intermittent HD)

27
New cards

Medications LESS Likely to Be Removed by HD / PD:

  • Increased (large) molecular weight

  • Highly protein-bound

  • Increased (large) volume of distribution (Vd) (sequestered in tissues rather than serum)

    • Ionized drugs